中国经济网北京8月27日讯 神马电力(603530.SH)昨日晚间发布《关于持股5%以上股东减持股份计 划公告》。 公告显示，公告发布之日起15个交易日后的3个月内，陈小琴拟通过集中竞价交易和大宗交易方式 合计减持不超过12,950,536股，即不超过公司总股本的3%。其中，以集中竞价方式减持不超过4,316,845 股（不超过公司总股本的1%），以大宗交易方式减持不超过8,633,691股（不超过公司总股本的2%）。 若计划减持期间公司发生送股、资本公积转增股本等股份变动事项，减持股份数量相应调整。 截至公告披露日，公司持股5%以上股东陈小琴持有公司无限售流通股份71,702,102股，占公司总股 本的16.61%，其所持股份全部来源于公司首次公开发行前股份。 神马电力2025年半年度募集资金存放与实际使用情况专项报告显示，根据中国证券监督管理委员会 于2021年2月8日签发的证监许可[2021]346号文《关于核准江苏神马电力股份有限公司非公开发行股票 的批复》，公司于2021年8月非公开发行人民币普通股32,218,837股，每股发行价格为人民币13.16元， 募集资金总额为人民币42,399.99万元 ...

Core Viewpoint - The company, Jiuwu High-Tech, plans to issue convertible bonds to raise a total of up to RMB 504 million for various projects and working capital [1][2]. Fundraising Details - The total amount to be raised from the issuance of convertible bonds is RMB 504 million, which will be allocated to three main projects: 1. A pilot production line for lithium chloride with an annual capacity of 2,000 tons at Bangocuo Salt Lake, requiring RMB 170 million [2]. 2. A production line for special inorganic membrane components and devices, requiring RMB 210 million [2]. 3. Supplementing working capital, requiring RMB 124 million [2]. - The total investment for these projects amounts to RMB 553.79 million [2]. Convertible Bond Specifications - The convertible bonds will be issued at a par value of RMB 100 each and will have a term of six years from the date of issuance [2][3]. - The interest on the bonds will be paid annually, with the principal and final interest due at maturity [3]. - The issuance will be open to various investors, including individuals and institutions, with specific exclusions as per legal regulations [3]. Previous Fundraising Activities - The company previously raised RMB 254 million through the issuance of convertible bonds in 2020, with a net amount of RMB 245.58 million after deducting fees [5]. - In 2021, the company raised approximately RMB 102.99 million through a simplified procedure for issuing shares to specific investors [6]. - Over the past five years, the company has raised a total of RMB 357 million through two fundraising activities [7].

Group 1 - The controlling shareholder and actual controller of Zhida Mai, Sui Guodong, plans to reduce his shareholding by up to 5,965,657 shares, accounting for 3% of the total share capital, to repay pledged financing debts and for personal funding needs [1] - As of the latest report, Sui Guodong holds 73,042,476 shares, representing 36.73% of the total share capital, and 22,230,000 shares are pledged, which is 11.18% of the total share capital [1] - The second-largest shareholder, Liu Feng, has 3,380,000 shares pledged, bringing the total pledged shares of both shareholders to 12.88% of the total share capital [1] Group 2 - Zhida Mai raised a total of 378.93 million yuan from its initial public offering, with a net amount of 329.99 million yuan after expenses [2] - The company aimed to raise 33 million yuan for the upgrade of its personalized technology platform based on big data [2] - The total expenses for the issuance amounted to 48.93 million yuan, including underwriting and sponsorship fees of 33 million yuan [2] Group 3 - In 2020, Zhida Mai raised 728 million yuan through a private placement, issuing 8,196,437 shares at a price of 88.88 yuan per share [3] - The actual net amount raised from this issuance was approximately 713 million yuan after deducting various fees [3] - The funds raised were deposited in a dedicated account, and a tripartite supervision agreement was signed with the underwriter and the bank [3] Group 4 - The total amount raised by Zhida Mai from the two fundraising activities is 1.107 billion yuan [4]

中国经济网北京8月18日讯 新诺威(300765.SZ)近日披露2025年半年度报告。 2025年1-6月，公司实现营业收入10.50亿元，同比增长7.99%；归属于上市公司股东的净利润 为-274.61万元，上年同期为1.37亿元；归属于上市公司股东的扣除非经常性损益的净利润为-4,114.41万 元，上年同期为1.34亿元；经营活动产生的现金流量净额为-1.52亿元，上年同期为-9.41亿元。 公司上市前披露的招股说明书显示，公司拟募集资金114,240.92万元，用于保健食品和特医食品生 产项目，保健品研发中心建设项目，营销体系建设项目，新建保健品软胶囊产业化项目，咖啡因系列产 品节能减排技术升级改造项目。 公司发行费用合计8,109.08万元，其中承销及保荐费用7,127.13万元。 截至今日收盘，新诺威报51.21元，跌幅3.38%，总市值719.29亿元。 2022年至2024年，公司营业收入分别为28.38亿元、25.39亿元、19.81亿元，归属于上市公司股东的 净利润分别为5.03亿元、4.34亿元、5,372.63万元，归属于上市公司股东的扣除非经常性损益的净利润分 别为6.58亿元、7. ...

中国经济网北京8月13日讯 曼卡龙(300945.SZ)昨日晚间披露关于控股股东减持股份预披露公告。 持有公司股份99,280,000股（占公司总股本比例37.8828%）的控股股东浙江万隆曼卡龙投资有限公司（简称"万隆曼卡 龙"）计划在公告披露之日起十五个交易日后的三个月内（即2025年9月3日至2025年12月2日）以集中竞价方式和大宗交易 方式减持公司股份合计不超过7,862,148股，其中任意连续90日内以集中竞价方式减持不超过2,620,716股（占公司总股本比 例1%），任意连续90日内通过大宗交易方式减持不超过5,241,432股（占公司总股本比例2%），即合计不超过公司总股本 的3%。 | | | | | | | 自本公告 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 之日起十 | 按照减持 | | | | 首次公开 | | | | 五个交易 | 实施时的 | | 万降曼 | 股东 | 发行股票 | | | 集中竞 | 日后的三 | 市场价格 | | 卡龙 | 资金 | 前已发行 | 7,862,148 ...

Group 1 - The report indicates a decline in the 2-year and 10-year Treasury yields in the US, with the 10-year yield falling to 4.23% and the 2-year yield to 3.69% during the week of July 28 to August 1 [3][22][23] - The report highlights a significant net inflow of southbound funds, totaling 819.5 billion yuan year-to-date, with major inflows into non-bank financials (+13 billion yuan), pharmaceuticals (+10.66 billion yuan), and electronics (+3.79 billion yuan) [6][44][47] - The report notes a decrease in financing buy-in amounts, averaging 189.3 billion yuan, which represents a 0.4% week-on-week decline, while the proportion of financing buy-in to total A-share trading volume increased [7][51] Group 2 - In July, 135 new funds were established, with 78 being equity funds, totaling approximately 35.5 billion units issued, compared to 83 funds in July 2024 [6][29][33] - The report states that 32 new equity ETFs were launched in July, with a total issuance of 13.9 billion units, reflecting a significant increase from the previous year [6][35][39] - The report mentions that the IPO activity in July included 8 companies raising approximately 24.2 billion yuan, with a total equity financing scale of about 66.2 billion yuan [7][56]

登录新浪财经APP 搜索【信披】查看更多考评等级 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本报告第三节"管理层讨 论与分析"中"风险因素"相关的内容。 1.3本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.4公司全体董事出席董事会会议。 1.5本半年度报告未经审计。 1.6董事会决议通过的本报告期利润分配预案或公积金转增股本预案 1、公司拟以实施权益分派股权登记日登记的存托凭证总数扣减公司回购专用证券账户中的存托凭证份 数为基数，拟向全体存托凭证持有人每10份派发现金红利4.23元（含税）。截至2025年8月1日，公司存 托凭证总数为719,444,662份，以扣除公司回购专用证券账户中的9,409,705份存托凭证后的710,034,957份 存托凭证为基数，以此计算合计拟派发现 ...

Core Viewpoint - Dongya Pharmaceutical (605177.SH) is expected to report a significant loss in the first half of 2025, with net profit projected to be between -28 million to -35 million yuan, contrasting sharply with a profit of 32.47 million yuan in the same period last year [1][2]. Financial Performance - In 2024, the company reported operating revenue of 1.198 billion yuan, a decrease of 11.66% year-on-year [2]. - The net profit attributable to shareholders was -101 million yuan, representing a year-on-year decline of 183.02% [2]. - The net profit after excluding non-recurring gains and losses was -98.41 million yuan, down 191.03% year-on-year [2]. - The net cash flow from operating activities was -157 million yuan [2]. Shareholder Structure - The actual controllers of Dongya Pharmaceutical are Chi Zhengming and Chi Cheng, who together hold significant voting rights in the company [1]. - Chi Zhengming directly owns 41.06% of the shares, while Chi Cheng holds 6.79% directly and has additional influence through a partnership [1]. Fundraising and Use of Proceeds - Dongya Pharmaceutical has raised a total of 1.574 billion yuan through two fundraising rounds since its listing [4]. - The company raised 688 million yuan through the issuance of convertible bonds, with a net amount of approximately 680 million yuan after deducting issuance costs [3]. - The funds raised are allocated for projects including the production of key intermediates for cephalosporin antibiotics and upgrading raw material production [2].

Fundraising Plan - The company plans to raise a total of 956,340,000.00 yuan through a private placement, with the net proceeds to be used entirely for debt repayment and to supplement working capital [1][2] Necessity and Feasibility Analysis - The necessity of the fundraising is highlighted by the company's significant debt, totaling approximately 1.512 billion yuan, with a high asset-liability ratio of 85.75% as of the end of 2024. The current cash balance of 118 million yuan is insufficient to cover these debts [1][2] - The feasibility of the fundraising is supported by its alignment with relevant policies and regulations, as well as the company's operational needs. The funds will help optimize the capital structure and enhance debt repayment capacity [2][3] Impact on Financial Status and Management - The fundraising is expected to positively impact the company's financial status by significantly increasing total assets and net assets, thereby improving the asset structure and reducing the asset-liability ratio [3][4] - The funds will alleviate debt pressure, enhance financial stability, and support ongoing business operations and product innovation, ultimately improving competitiveness and profitability [2][4] Governance and Fund Management - The company has established a governance structure in line with listing standards, ensuring independent operation of the board and management. A fundraising management system is in place to oversee the use of raised funds [3][4]

中国经济网北京7月24日讯 宏昌科技（301008）(301008.SZ)昨日晚间发布关于公司股东减持股份的预披 露公告。公司于近日收到股东股东金华宏盛企业管理合伙企业(有限合伙)（以下简称"金华宏盛"）和金 华宏合企业管理合伙企业(有限合伙)（以下简称"金华宏合"）出具的《关于股份减持计划的告知函》。 金华宏盛、金华宏合计划在公告披露之日起15个交易日之后3个月内以集中竞价交易方式或大宗交易方 式进行减持。其中，金华宏盛、金华宏合以集中竞价方式合计减持不超过1,297,600股（占公司总股本的 1%），金华宏盛、金华宏合以大宗交易方式合计减持不超过2,018,700股（占公司总股本的1.56%），合 计不超过3,316,300股，占公司总股本的2.56%。 公司股东金华宏盛（持有公司股份2,856,000股，占公司总股本的2.20%）、金华宏合（持有公司股份 2,184,000股，占公司总股本的1.68%）是公司的员工持股平台，公司实际控制人陆宝宏担任其执行事务 合伙人。 宏昌科技首次公开发行保荐机构为国信证券股份有限公司，保荐代表人为唐帅、傅国东。宏昌科技发行 费用总额为8079.24万元，其中，国信证券 ...